Virtual Screening (VS) is the screening of active compounds based on small molecule databases. Using molecular docking between small molecules and drug targets, VS can rapidly select active compounds with drug discovery potential from tens to millions of molecules, greatly reducing the number of compounds screened, shortening the research cycle and reducing the cost of drug development. With a reported positive rate of 5%-30%, virtual screening has become the most promising drug development tool as more and more cases of successful drug design have been reported year by year.

    The ULS molecular simulation team has many years of experience in drug design and industry-recognized success stories for a variety of targets. ULS has rich database resources and high performance computer servers to provide professional molecular docking and virtual screening services. Optimized virtual screening solutions can massively reduce the number of compounds to be experimentally screened, increase the likelihood of ideal precursor discovery, shorten the virtual screening service time, and reduce the risk of failure of late precursor optimization. We can tailor our services to meet specific needs and provide quality early-stage drug discovery services to our research clients.